{"id":"W4289878834","doi":"10.1093/noajnl/vdac078.029","title":"CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32)","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Temozolomide; Medicine; Internal medicine; Oncology; Clinical endpoint; Progression-free survival; Phases of clinical research; Radiation therapy; Clinical trial; Adverse effect; Cancer; Chemotherapy; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00127896,0.001053502,0.001369612,0.0004110399,0.0003841542,0.0009235805,0.0007692985,0.001149533,0.005716633],"category_scores_gemma":[0.0005899728,0.000262992,0.001072446,0.0003505898,0.000600883,0.00072438,0.0003120319,0.002660648,0.001205688],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001306614,"about_ca_system_score_gemma":0.001560284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001307999,"about_ca_topic_score_gemma":0.006587465,"domain_scores_codex":[0.9997407,0.00009970706,0.00001434081,0.00004472067,0.00003395019,0.00006663563],"domain_scores_gemma":[0.9996494,0.00002816794,0.00007455832,0.00002248463,0.00002781963,0.0001976052],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6495013,0.02512961,0.005221356,0.00333251,0.001903426,0.0004083177,0.0001669664,0.003189192,0.02854314,0.001920904,0.06542572,0.2152574],"study_design_scores_gemma":[0.7936941,0.1701666,0.008917863,0.0003188047,0.0008612259,0.0004925947,0.00006784954,0.002330763,0.003903939,0.001356658,0.01783464,0.00005503087],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.94322,0.01718085,0.00158409,0.004383442,0.001103399,0.007614316,0.009948009,0.0006159258,0.01435002],"genre_scores_gemma":[0.9376153,0.009180824,0.004657032,0.00743281,0.0005079007,0.01166213,0.01528718,0.0001422943,0.01351455],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005716633,"threshold_uncertainty_score":0.01912403,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02669825263285219,"score_gpt":0.3462762793236294,"score_spread":0.3195780266907772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}